NEW
YORK, Sept. 27, 2022 /CNW/ -- Mind Medicine
(MindMed) Inc. ("MindMed") (NASDAQ: MNMD) (NEO: MMED), a clinical
stage biopharmaceutical company developing novel products to treat
brain health disorders, today announced the pricing of its
underwritten public offering of 7,058,823 common shares, together
with accompanying warrants to purchase 7,058,823 common shares. The
combined offering price to the public of each common share and
accompanying warrant is $4.25. Each
common share will be sold in combination with an accompanying
warrant, and each warrant is exercisable to purchase one common
share. The accompanying warrant will be immediately exercisable and
has an exercise price of $4.25 per
common share and expires five years from the date of issuance.
All of the securities are being sold by MindMed. The gross
proceeds from the offering to MindMed are expected to be
approximately $30 million, before
deducting underwriting discounts and commissions and offering
expenses. The offering is expected to close on or about
September 30, 2022, subject to
customary closing conditions. No distribution under the
underwritten public offering shall occur in Canada or to a person resident in Canada.
RBC Capital Markets and Cantor are acting as lead joint
book-running managers for the offering. Oppenheimer & Co. is
acting as a joint book-running manager for the offering.
A shelf registration statement relating to this offering was
filed with the Securities and Exchange Commission ("SEC") on
May 4, 2022, and declared effective
by the SEC on May 16, 2022. The
offering is being made only by means of a written prospectus and
prospectus supplement that form a part of the registration
statement. A preliminary prospectus supplement and
accompanying prospectus relating to the offering have been filed
with the SEC and are available on the SEC's website at www.sec.gov
or on SEDAR at www.sedar.com. A final prospectus supplement
and accompanying prospectus will be filed with the SEC and will be
available on the SEC's website at www.sec.gov or on SEDAR at
www.sedar.com. When available, copies of the final prospectus
supplement and the accompanying prospectus may also be obtained by
contacting RBC Capital Markets, Attention: Equity Capital Markets,
200 Vesey Street, 8th Floor, New York,
NY 10281, or by telephone at (877) 822-4089 or by email at
equityprospectus@rbccm.com or by contacting Cantor Fitzgerald &
Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor,
New York, NY 10022, or by email at
prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders. We are developing a
pipeline of innovative drug candidates, with and without acute
perceptual effects, targeting the serotonin, dopamine and
acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED.
Forward-Looking
Statements
Certain statements in this news release related to MindMed
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "will", "may", "should", "could",
"intend", "estimate", "plan", "anticipate", "expect", "believe",
"potential" or "continue", or the negative thereof or similar
variations. Forward-looking information in this news release
includes, but is not limited to, the uncertainties related to
market conditions and the completion of the public offering on the
anticipated terms or at all. There are numerous risks and
uncertainties that could cause actual results and MindMed's plans
and objectives to differ materially from those expressed in the
forward-looking information, such as those risks discussed or
referred to herein and the risks described in MindMed's Annual
Report on Form 10-K for the fiscal year ended December 31, 2021 and its Quarterly Report on
Form 10-Q for the period ended June 30,
2022 under headings such as "Special Note Regarding
Forward-Looking Statements," and "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and other filings and furnishings made by MindMed with
the securities regulatory authorities in all provinces and
territories of Canada which are
available under MindMed's profile on SEDAR at www.sedar.com and
with the SEC on EDGAR at www.sec.gov. Except as required by law,
MindMed undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in expectations or
otherwise.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-announces-pricing-of-public-offering-of-common-shares-and-warrants-301635020.html
SOURCE Mind Medicine (MindMed) Inc.